

Fax

FAX RECEIVED

JAN 0 9 2001

GROUP 1600

Legal Department 3160 Porter Drive Palo Alto, CA 94304 phone 650.855.0555 fax 650.845.4166 Or

50.845.4166 or 650.849.8886

DATE:

January 8, 2001

TO:

Examiner Slobodyanski

COMPANY:

USPTO

FAX NO.:

703-308-4242

TELEPHONE NO .:

703-306-3222

FROM:

-P. Ben-Wang-

OUR REF. NO.:

PF-0148-3 CPA

YOUR REF. NO.:

09/415,540

PAGES:

_ <

Please see the attached.

This facsimile is intended for the addressee only and may contain confidential information. If you have received this facsimile in error, please call us at 650.855.0555 immediately to arrange for its return.

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the attention of Examiner Slobodyauski, E., Group Art Unit 1652, U.S. Patent and Trademark Office to Facsimile No. 703-308-4242 on the date shown below.

Phillip R. Hawkins

01 PUni31

FAX RECEIVED

PF-0148-3 CPA

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity) (Only for Continuation or Divisional Applications Under 37 CFR 1.53(d) Docket No. Total Pages First Named Inventor

> Address to: Commissioner for Patents Box CPA Washington, D.C. 20231

--Two (2)

This is a request for filing a 2 continuation D divisional application under 37 CFR 1.53(d), (continued application (CPA)) of prior application number 09/415,540 filed on October 8, 1999, and entitled: NOVEL HUMAN **PYROPHOSPHATASE**

Under 37 CFR 1.116 in the Enter the unentered amendment previously filed on 1, 0 prior nonprovisional application. A preliminary amendment is enclosed (2 pp.) This application is being filed by less than all the inventors named in the prior application. In 3. 🗆 accordance with 37 CFR 1.53(d), the Commissioner is requested to delete the name(s) of the following person of persons who are named as inventors in the prior nonprovisional application but are not 01/09/2001 GYIRHILL 0000 inventors of the invention being claimed in this application: 710.00 A new power of attorney is enclosed. 4. An Information Disclosure Statement (IDS) is enclosed: 5. 🗀 b. 口图 Copies of IDS Citations a. DØ PTO-1449 The fee for this application is calculated as follows: 6. ×

CLAIMS AS FILED

Multiple Dependen	t Cloim(s), If any		+ \$270			
	<u> </u>					\$
Indep. Claims	1	-3	0	x \$80		\$0
Total Claims	5	-20	0	x \$18		\$0
Chine	Phamber Flieti	Mines		Other T Smoll &a Rate	ID	flugie fice S710-mi



JAN 0 9 2001

Docket No. PF-0148-3 CPA

7. 🗷		The Commissioner is hereby authorized to charge DepGRACONTRO. 16008 in the amount of \$ 710.00							
8. ਲ਼			The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 09-0108						
		 fees required under 37 C.F.R. 1.16. fees required under 37 C.F.R. 1.17. fees required under 37 C.F.R. 1.18 							
9. 🗆		Also enclosed:							
		. ee ee							
•									
10.⊠		The prior application	on's correspondence address dress is provided below:	will carry over to this CPA UNLESS	a new				
. *									
-		This	transmittal is being submit	ted in duplicate for fee processing.					
			· .						
Date	d: <u>Ja</u>	nuary 8 ,2001		Signature					
			*	P. Ben Wang, J.D. Typed or printed name					
				41,420 Registration Number (if applicable	e)				
		d		□⊠ Inventor(s) □⊠ Assignee of complete interest					

Docket No.: PF-0148-3 CPA

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the attention of Examiner Slobodyanski, E., Group Art Unit 1652, U.S. Patent and Trademark

Office to Facsimile Noy 703-308-4242 on the date shown below

Signature Signature

//8/0/ Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hawkins et al.

Title:

HUMAN PYROPHOSPHATASE

Serial No.:

09/415,540

Filing Date:

October 8, 1999

Examiner:

Slobodyansky, E.

Group Art Unit:

1652

Box CPA

Commissioner for Patents Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination of the above-identified Continued Prosecution Application, the request for which is attached, please amend the specification as follows:

IN THE CLAIMS

Please amend claim 19 as indicated below. For the Examiner's convenience, the non-amended pending claims are also listed below.

18. (Reiterated) The method of claim 20, wherein before hybridization, the target polynucleotide is amplified by the polymerase chain reaction.

19 (Twice amended) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:2,

b) a naturally-occurring human polynucleotide sequence variant encoding an amino acid sequence having

at least 90% sequence identity to the sequence of SEQ ID NO:1 and

c) a polynucleotide sequence complementary to a) or b).

20. (Reiterated) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 19, comprising

1

71605

09/415,540

4 7688 ON